Moody’s signals bigger risks for PBMs amid pricing backlash

Criticism of rising prescription drug prices has brought the threat to tighter regulation and scrutiny to the pharmaceutical industry, but a new report from Moody’s signals that pharmacy benefit managers (PBMs) are likely to share some of that backlash as well. ¬†Read more…

BioPharma Dive

Jacob Bell @RealJacobBell